Organon (OGN) Upgraded to Strong Buy: What Does It Mean for the Stock?
Organon (OGN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Organon (OGN). This makes it worthwhile to examine what the stock has in store.
Organon (OGN) Increases Yet Falls Behind Market: What Investors Need to Know
In the closing of the recent trading day, Organon (OGN) stood at $20.81, denoting a +0.39% change from the preceding trading day.
Organon (OGN) Stock Drops Despite Market Gains: Important Facts to Note
In the most recent trading session, Organon (OGN) closed at $19.93, indicating a -1.04% shift from the previous trading day.
Organon (OGN) Stock Sinks As Market Gains: Here's Why
In the most recent trading session, Organon (OGN) closed at $20.63, indicating a -0.77% shift from the previous trading day.
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Organon (OGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Organon (OGN) Advances While Market Declines: Some Information for Investors
Organon (OGN) closed the most recent trading day at $20.45, moving +0.49% from the previous trading session.
Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It
Zacks.com users have recently been watching Organon (OGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Organon (OGN) Just Overtook the 20-Day Moving Average
From a technical perspective, Organon (OGN) is looking like an interesting pick, as it just reached a key level of support. OGN recently overtook the 20-day moving average, and this suggests a short-term bullish trend.
Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know
Organon (OGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Natixis Advisors L.P. Has $396,000 Stake in Organon & Co. (NYSE:OGN)
Natixis Advisors L.P. reduced its stake in shares of Organon & Co. (NYSE:OGN – Free Report) by 4.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 27,495 shares of the company’s stock after selling 1,285 shares during the quarter. Natixis Advisors L.P.’s holdings in Organon & Co. were worth $396,000 as of its most recent SEC filing. A number of other hedge funds and other institutional investors also recently made changes to their positions in OGN. Lindbrook Capital LLC increased its position in shares of Organon & Co. by 348.3% during the 4th quarter. Lindbrook Capital LLC now owns 1,838 shares of the company’s stock worth $27,000 after purchasing an additional 1,428 shares in the last quarter. Harvest Fund Management Co. Ltd increased its holdings in shares of Organon & Co. by 495.5% during the third quarter. Harvest Fund Management Co. Ltd now owns 1,602 shares of the company’s stock worth $28,000 after buying an additional 1,333 shares in the last quarter. Headlands Technologies LLC bought a new position in shares of Organon & Co. in the third quarter valued at approximately $35,000. GAMMA Investing LLC acquired a new position in shares of Organon & Co. in the 4th quarter worth approximately $38,000. Finally, EverSource Wealth Advisors LLC grew its position in Organon & Co. by 97.7% during the 3rd quarter. EverSource Wealth Advisors LLC now owns 2,246 shares of the company’s stock worth $39,000 after acquiring an additional 1,110 shares during the last quarter. 77.43% of the stock is owned by institutional investors. Insiders Place Their Bets In other Organon & Co. news, insider Kirke Weaver bought 2,720 shares of Organon & Co. stock in a transaction dated Thursday, February 22nd. The shares were bought at an average price of $18.36 per share, with a total value of $49,939.20. Following the purchase, the insider now owns 15,181 shares of the company’s stock, valued at $278,723.16. The transaction was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 1.17% of the company’s stock. Organon & Co. Stock Performance OGN stock opened at $21.80 on Monday. The company has a 50 day moving average price of $18.82 and a 200 day moving average price of $16.16. Organon & Co. has a fifty-two week low of $10.84 and a fifty-two week high of $24.08. The company has a debt-to-equity ratio of 181.35, a current ratio of 1.65 and a quick ratio of 1.15. The stock has a market capitalization of $5.61 billion, a PE ratio of 5.33, a price-to-earnings-growth ratio of 0.94 and a beta of 0.81. Organon & Co. (NYSE:OGN – Get Free Report) last released its earnings results on Thursday, February 15th. The company reported $0.87 earnings per share for the quarter, topping analysts’ consensus estimates of $0.73 by $0.14. Organon & Co. had a negative return on equity of 360.57% and a net margin of 16.50%. The company had revenue of $1.60 billion during the quarter, compared to the consensus estimate of $1.55 billion. Analysts forecast that Organon & Co. will post 4.3 EPS for the current year. Organon & Co. Announces Dividend The company also recently disclosed a quarterly dividend, which will be paid on Thursday, June 13th. Shareholders of record on Monday, May 13th will be issued a dividend of $0.28 per share. The ex-dividend date of this dividend is Friday, May 10th. This represents a $1.12 annualized dividend and a yield of 5.14%. Organon & Co.’s dividend payout ratio is currently 27.38%. Analyst Ratings Changes Several equities analysts have issued reports on OGN shares. The Goldman Sachs Group lifted their price objective on Organon & Co. from $18.00 to $20.00 and gave the company a “neutral” rating in a research report on Friday, May 3rd. Piper Sandler lifted their price target on Organon & Co. from $22.00 to $24.00 and gave the company an “overweight” rating in a report on Monday, April 29th. Get Our Latest Stock Report on Organon & Co. About Organon & Co. (Free Report) Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.
